Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alaunos Therapeutics ( (TCRT) ) just unveiled an announcement.
On December 17, 2025, Alaunos Therapeutics, Inc. entered into a Settlement and Release Agreement with The University of Texas M.D. Anderson Cancer Center to resolve disputes over unpaid invoices tied to a 2019 research and development agreement. Alaunos agreed to pay a total of $285,055 to MD Anderson in a series of installments running from late December 2025 through May 30, 2026, and both parties granted mutual general releases of claims related to the unpaid invoices, with limited exceptions for breaches of the settlement and certain ongoing matters such as Protocol 2006-0676, effectively closing a financial and legal overhang on their prior collaboration.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Alaunos Therapeutics, Inc. is a biotechnology company focused on cancer research and development, working with leading academic medical centers such as The University of Texas M.D. Anderson Cancer Center to advance oncology-related programs under sponsored research agreements.
Average Trading Volume: 445,405
Technical Sentiment Signal: Hold
Current Market Cap: $7.95M
For an in-depth examination of TCRT stock, go to TipRanks’ Overview page.